155 related articles for article (PubMed ID: 24090045)
1. Can the pharmaceutical industry embrace comparative effectiveness research? A view from inside.
Berger ML
Expert Rev Pharmacoecon Outcomes Res; 2013 Oct; 13(5):565-8. PubMed ID: 24090045
[No Abstract] [Full Text] [Related]
2. Portfolio analysis and R&D decision making.
Evans R; Hinds S; Hammock D
Nat Rev Drug Discov; 2009 Mar; 8(3):189-90. PubMed ID: 19182818
[No Abstract] [Full Text] [Related]
3. NINDS common data element project: a long-awaited breakthrough in streamlining trials.
Stone K
Ann Neurol; 2010 Jul; 68(1):A11-3. PubMed ID: 20583225
[No Abstract] [Full Text] [Related]
4. Deals landscape: notable deals in the pharmaceutical industry in the first quarter of 2008.
Shumoogam J; Al-Shamahi A
IDrugs; 2008 May; 11(5):351-5. PubMed ID: 18465677
[TBL] [Abstract][Full Text] [Related]
5. Deal watch: Trends in platform technology deal-making.
Walker J; Jacob J
Nat Rev Drug Discov; 2009 Dec; 8(12):923. PubMed ID: 19949395
[No Abstract] [Full Text] [Related]
6. Misleading congress about drug development: Reply.
Dimasi JA; Hansen RW; Grabowski HG
J Health Polit Policy Law; 2008 Apr; 33(2):319-24; discussion 325-7. PubMed ID: 18325904
[TBL] [Abstract][Full Text] [Related]
7. The case for less, not more, US FDA regulation.
Vernon JA; Golec JH
Pharmacoeconomics; 2011 Aug; 29(8):637-40. PubMed ID: 21732703
[No Abstract] [Full Text] [Related]
8. Comparative effectiveness research: Promising area of study for pharmacists.
Clancy CM
J Am Pharm Assoc (2003); 2010 Mar-Apr 1; 50(2):131-3. PubMed ID: 20199952
[No Abstract] [Full Text] [Related]
9. GAO report says drug R & D costs rising, innovation decreasing.
Consult Pharm; 2007 Mar; 22(3):257-8. PubMed ID: 17691159
[No Abstract] [Full Text] [Related]
10. Communication about results of comparative effectiveness studies: a pharmaceutical industry view.
Perfetto EM; Bailey JE; Gans-Brangs KR; Romano SJ; Rosenthal NR; Willke RJ
Health Aff (Millwood); 2012 Oct; 31(10):2213-9. PubMed ID: 23048099
[TBL] [Abstract][Full Text] [Related]
11. Aligning pharmaceutical innovation with medical need.
Nathan C
Nat Med; 2007 Mar; 13(3):304-8. PubMed ID: 17342145
[No Abstract] [Full Text] [Related]
12. Healthcare ROI. Medical research, comparative-effectiveness studies deserve investment.
May D
Mod Healthc; 2013 Feb; 43(8):23. PubMed ID: 23516786
[No Abstract] [Full Text] [Related]
13. Emerging analytical techniques for comparative effectiveness research.
Brunelli SM; Rassen JA
Am J Kidney Dis; 2013 Jan; 61(1):13-7. PubMed ID: 23021799
[No Abstract] [Full Text] [Related]
14. [Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].
Hedner T; Gatenbeck L
Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1280-1. PubMed ID: 22852257
[No Abstract] [Full Text] [Related]
15. The hunt for a new drug: five views from the inside.
Mervis J
Science; 2005 Jul; 309(5735):722. PubMed ID: 16051781
[No Abstract] [Full Text] [Related]
16. Drug discovery alliances.
Jones A; Clifford L
Nat Rev Drug Discov; 2005 Oct; 4(10):807-8. PubMed ID: 16237845
[No Abstract] [Full Text] [Related]
17. Looking at CER from the pharmaceutical industry perspective.
Dubois RW
J Manag Care Pharm; 2012 May; 18(4 Suppl A):S9-12. PubMed ID: 22578212
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness research in kidney disease: a national priority.
Boulware LE
Am J Kidney Dis; 2013 Jan; 61(1):9-12. PubMed ID: 22959713
[No Abstract] [Full Text] [Related]
19. Pfizer slashes R&D.
Cressey D
Nature; 2011 Feb; 470(7333):154. PubMed ID: 21307908
[No Abstract] [Full Text] [Related]
20. Biomarkers: a valuable tool in clinical research and medical practice.
Carini C
IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
